Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
6.4700
-0.1200 (-1.82%)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development
By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need.
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024.
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is stalled
The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint.
